72076 Tübingen, de
+49 (7071) 5397-110
Immatics Proprietary Target Selected for the Development of Cancer Immunotherapies
The target was identified and validated using Immatics’ world-leading XPRESIDENT® technology platform. Successful development and subsequent commercialization of cancer immunotherapies directed against this target would trigger payment of additional development and sales milestones by Roche to Immatics, as well as royalty payments on worldwide net sales.
Dr Harpreet Singh, Chief Scientific Officer at Immatics, said: “We are very pleased to see that a novel immunotherapy directed against an Immatics target is progressed towards the clinic. This is yet another validation from a global leader in oncology of the quality and potential of the XPRESIDENT® platform and Immatics’ targets for cancer therapy.”
About XPRESIDENT® Technology
XPRESIDENT® is the most sensitive, accurate and highest-throughput technology capable of identifying targets in virtually any type of cancer. This proprietary technology provides novel, highly-specific, and safe cancer targets that are pivotal for developing a range of powerful immunotherapies with the potential to cure cancer. The cancer targets identified by XPRESIDENT® are peptides presented by human leukocyte antigen (HLA) receptors on the surface of tumor cells. Classical antibody and CAR-T therapies are restricted to cell surface proteins, which constitute only about 20-25% of all available targets on a solid tumor. XPRESIDENT® unlocks all intracellular antigens, increasing the target space by more than 4-fold.
For regular updates about Immatics, visit www.immatics.com.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.